Annexon, Inc. Stock Price, News & Analysis

Annexon announced encouraging interim data from its Phase 2 study of ANX005 for Huntington’s Disease, showing positive tolerance and engagement at the six-month mark. Financially, the company reported a net loss of $37.4 million for Q4 2021, totaling $130.3 million for the year. As of December 31, 2021, Annexon had $242.7 million in cash, expected to fund operations into Q1 2024. Key milestones include further data releases for ANX005 and ANX009 in 2022, indicating a robust pipeline aimed at addressing complement-mediated diseases.

Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that CEO Douglas Love will join the “Orphan CNS Panel” at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 2:10 p.m. ET. The panel focuses on complement-mediated conditions affecting the CNS. A live webcast will be available on Annexon's Investors page and will remain archived for 30 days post-event. Annexon is pioneering complement-targeting medicines aimed at autoimmune and neurodegenerative disorders, with a pipeline that includes three clinical-stage drug candidates and various early-stage programs.

Annexon, a clinical-stage biopharmaceutical company, announced the appointment of Bettina M. Cockroft, M.D., to its board of directors. Cockroft, who is currently the chief medical officer at Sangamo Therapeutics, brings nearly 20 years of experience in clinical organizations focused on neurodegenerative disorders. Annexon is advancing therapies for complement-mediated diseases, including Guillain–Barré Syndrome and Huntington’s Disease, with multiple data readouts expected over the next two years. This leadership change aims to enhance the company’s expertise in its novel complement-focused therapies.

Annexon (Nasdaq: ANNX) announced interim results from its ongoing Phase 2 trial of ANX005 for Huntington's disease (HD), showing encouraging safety and efficacy. The treatment demonstrated full target engagement of C1q in cerebrospinal fluid, with over 50% of evaluable patients maintaining clinical function. In patients with excess complement activity, 75% showed improvement in clinical measures. No serious adverse infections or deaths were reported. Full data is expected in Q2 2022, with plans for a Phase 3 trial pending results.

Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that its CEO, Douglas Love, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 p.m. ET. The presentation will focus on their innovative complement medicines targeting autoimmune and neurodegenerative disorders. A live webcast will be available on their website, with a replay accessible for 30 days post-event.

Annexon's pipeline includes product candidates like ANX005, ANX007, and ANX009, designed to disrupt the C1q pathway.

Annexon announced positive safety and dose-response results from its Phase 1 trial of ANX009, designed to block C1q in autoimmune diseases. The study, involving 48 healthy volunteers, showed no serious adverse events and effective C1q inhibition, supporting further trials. Additionally, preclinical findings presented at the ASH Annual Meeting indicated the classical complement pathway's role in warm autoimmune hemolytic anemia (wAIHA), with ongoing evaluations of ANX005 in a Phase 2 trial for this condition.

Annexon reported a net loss of $35.6 million or $0.93 per share for Q3 2021, compared to $15.6 million or $0.77 per share year-over-year. As of September 30, 2021, the company had $271.4 million in cash and investments, supporting operations into 2024. The FDA granted Orphan Drug designation for ANX005, aimed at treating Huntington's disease. The company is advancing three clinical-stage candidates in five trials, with initial data from ANX005 expected in Q4 2021. The leadership team has strengthened with new appointments, enhancing the company's research efforts.

Annexon, a clinical-stage biopharma company, has appointed Ted Yednock as Chief Innovation Officer and Larry Mattheakis as Chief Scientific Officer. Yednock, previously Chief Scientific Officer since 2013, will focus on strengthening scientific collaborations while remaining on the executive committee. Mattheakis brings extensive drug development experience from Protagonist Therapeutics, aiming to enhance Annexon’s therapeutic pipeline for complement-mediated diseases. The company is currently progressing three drug candidates across seven clinical trials, focusing on autoimmune, neurodegenerative, and ophthalmic disorders.

On September 23, 2021, Annexon (Nasdaq: ANNX), a biopharmaceutical company, announced that its CEO, Douglas Love, will speak at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 12:40 p.m. ET. The event will be available via a live webcast on Annexon's Investors page and will be archived for 30 days post-presentation. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, with a pipeline that includes innovative products like ANX005, ANX007, and ANX009.